Long-term treatment with proton pump inhibitor is associated with undesired weight gain

Table 1 Baseline demographics and characteristics of reflux patients treated with long-term daily maintenance proton pump inhibitor therapy and healthy controls (mean ± SD)

	Patients	Control	P
Number of subjects	52	58	-
Gender (male/female)	36/16	38/20	NS
Age (yr)	68.1 ± 10.4	68.8 ± 1.5	NS
Duration of observation (yr)			NS
PPI therapy	2.1 ± 1.1	-	-
Medical checkup	-	2.0 ± 0.4	-
Body weight (kg)	56.4 ± 10.4	58.6 ± 8.4	NS
Height (cm)	156.0 ± 9.8	156.0 ± 8.9	NS
Body mass index (kg/m2)	23.1 ± 3.1	24.1 ± 2.7	NS
Blood pressure (mmHg)			-
Systolic	133 ± 17	132 ± 16	NS
Diastolic	75 ± 11	75 ± 9	NS
Serum total protein (g/dL)	7.2 ± 0.3	7.2 ± 0.3	NS
Serum total cholesterol (mg/dL)	210 ± 39	210 ± 25	NS
Serum triglyceride (mg/dL)	121 ± 52	107 ± 43	NS

PPI: Proton pump inhibitor.

Table 2 Patient demographics

	Patients (n = 52)
Helicobacter pylori status
Negative	9
Positive	11
ND	32
Endoscopic findings
Normal	18
LA grade A	6
LA grade B	13
LA grade C	5
LA grade D	3
ND	7
Number of patients according to PPI regimens
Omeprazole 10 mg once daily	24
Omeprazole 20 mg once daily	12
Rabeprazole 10 mg once daily	8
Lansoprazole 15 mg once daily	5
Lansoprazole 30 mg once daily	3

LA: Los Angeles classification; ND: Not determined.

Table 3 Mean changes in nutritional parameters and blood pressure at the last visit compared to the baseline

	Patients (n = 52)	Control (n = 58)	P
Body weight (kg)	+2.2b	-0.1a	< 0.0001
Body mass index (kg/m2)	+0.92b	+0.15a	0.0005
Blood pressure (mmHg)			-
Systolic	+2.7	+1.9	NS
Diastolic	-0.6	-1.9	NS
Serum total protein (g/dL)	+0.014	+0.019	NS
Serum total cholesterol (mg/dL)	-9.1	-17.1	NS
Serum Triglyceride (mg/dL)	+3.1	+3.8	NS

^aNS vs baseline;

^bP < 0.0001 vs baseline; NS: Not significant.